The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Open accessPublished version of a preprint
Abstract
Blockade of the coinhibitory checkpoint molecule PD-1 has emerged as an effective treatment for many cancers, resulting in remarkable responses. However, despite successes in the clinic, most patients do not respond to PD-1 blockade. Metabolic dysregulation is a common phenotype in cancer, but both patients and tumors are metabolically heterogeneous. We hypothesized that the deregulated oxidative energetics of tumor cells present a metabolic barrier to antitumor immunity through the generation of a hypoxic microenvironment and that normalization of tumor hypoxia might improve response to immunotherapy. We show that the murine tumor lines B16 and MC38 differed in their ability to consume oxygen and produce hypoxic environments, which correlated with their sensitivity to checkpoint blockade. Metformin, a broadly prescribed type II diabetes treatment, inhibited oxygen consumption in tumor cells in vitro and in vivo, resulting in reduced intratumoral hypoxia. Although metformin monotherapy had little therapeutic benefit in highly aggressive tumors, combination of metformin with PD-1 blockade resulted in improved intratumoral T-cell function and tumor clearance. Our data suggest tumor hypoxia acts as a barrier to immunotherapy and that remodeling the hypoxic tumor microenvironment has potential to convert patients resistant to immunotherapy into those that receive clinical benefit. Cancer Immunol Res; 5(1); 9–16. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current studies have focused on the role of hypoxia-induced metabolic reprogramming in causing T cell dysfunction and exhaustion16,19,52–55.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 7×
“org Cancer Immunol Res; 5(1) January 2017 11”
BackgroundInfluentialGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331 · cited 2×
“can be metabolically plastic, and are primed to utilize glucose in oxygen-poor conditions, glucose, too, can be limiting in the tumor microenvironment (15,16).”
BackgroundMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“It is established that patients taking metformin for type II diabetes have a decreased risk of cancer (17, 18) and that much of the antitumor metformin effect can be attributed to T cells (19).”
BackgroundPosttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462 · cited 2×
“However, in the tumor microenvironment, as glucose is limiting, only cells able to effectively compete for glucose would experience an enhanced response (15, 16).”
BackgroundScharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
Self-citationAerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism
Peng, M., Yin, N., Chhangawala, S., Xu, K., Leslie, C. S., & Li, M. O. (2016) · Science · doi:10.1126/science.aaf6284 · Cited by 787 · cited 1×
“to effector function epigenetically and post-transcriptionally (26-28).”
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 708 · cited 1×
“We have previously shown that T cells in the tumor microenvironment are at a metabolic disadvantage and repress oxidative metabolism (13).”
BackgroundSelf-citation
Cited by
Sorted by citations
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 2,054
“These findings suggest that cellular metabolism might represent a crucial aspect of immunotherapeutics aimed at reversing T cell exhaustion, and indeed, metabolic drugs such as rapamycin (106, 117–119) and metformin (120) are being investigated.”
BackgroundMacrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837
Metabolic Instruction of Immunity
Buck, M. D., Sowell, R., Kaech, S. M., & Pearce, E. L. (2017) · Cell · doi:10.1016/j.cell.2017.04.004 · Cited by 1,270
“Indeed, respiratory supplementation of oxygen or treatment with metformin decreased intratumoral hypoxia and relieved several immunosuppressive features in the tumor microenvironment; the latter also served as an adjunct therapy that enhanced the antitumor effects of PD-1 blockade (Hatfield et al., 2015; Scharping et…”
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
“Metformin-mediated hypoxia reduction(205) enhances the antitumor effect of PD-1 inhibitor in cancer cells.(226) Hypoxia may predict who are irresponsive to metformin according to Sivalingam et al.”
BackgroundAutophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, Y., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,097
“Thus, Metformin (a ROS inhibitor) combined with PD-1 inhibition enhanced intratumor T cell activation and proliferation, resulting in tumor clearance and alleviating tumor inflammation through the decreased level of tumor hypoxia.(338) In addition to CTLs, multiple studies have shown that oxidative stress or ROS cause…”
BackgroundTargeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
Bader, J. E., Voss, K., & Rathmell, J. C. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.034 · Cited by 1,055
Scharping, N. E., Rivadeneira, D. B., Menk, A. V., Vignali, P. D. A., Ford, B. R., Rittenhouse, N. L., Peralta, R., Wang, Y., Wang, Y., DePeaux, K., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00834-9 · Cited by 897
Self-citationMetabolism of immune cells in cancer
Leone, R. D., & Powell, J. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0273-y · Cited by 877
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Kraehenbuehl, L., Weng, C., Eghbali, S. Z., Wolchok, J. D., & Merghoub, T. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00552-7 · Cited by 885
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Cha, J., Yang, W., Xia, W., Wei, Y., Chan, L.-C., Lim, S., Li, C.-W., Kim, T., Chang, S.-S., Lee, H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.030 · Cited by 785
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 670
Metabolites and the Tumour Microenvironment: From Cellular Mechanisms to Systemic Metabolism
Elia, I., & Haigis, M. C. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00317-z · Cited by 651
CD8+ T cell metabolism in infection and cancer
Reina‐Campos, M., Scharping, N. E., & Goldrath, A. W. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00537-8 · Cited by 657
Self-citationMetabolic barriers to cancer immunotherapy
DePeaux, K., & Delgoffe, G. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00541-y · Cited by 626
Self-citationReactive Oxygen Species in the Tumor Microenvironment: An Overview
Weinberg, F., Ramnath, N., & Nagrath, D. (2019) · Cancers · doi:10.3390/cancers11081191 · Cited by 502
“When mice were treated with the combination of metformin and PD-1 blockade improved intratumoral T-cell function and tumor clearance was observed [109].”
BackgroundInfluentialThe Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Therapeutic targeting of the hypoxic tumour microenvironment
Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 507
Menk, A. V., Scharping, N. E., Moreci, R. S., Zeng, X., Guy, C. S., Salvatore, S. R., Bae, H. R., Xie, J., Young, H. A., Wendell, S. G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.040 · Cited by 496
“In vitro cytotoxicity was assessed as previously described (Scharping et al., 2017).”
MethodSelf-citationPyroptosis: a new paradigm of cell death for fighting against cancer
Tan, Y., Chen, Q., Li, X., Zeng, Z., Xiong, W., Li, G., Li, X., Yang, J., Xiang, B., & Yi, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01959-x · Cited by 487
Metabolic and epigenetic regulation of T-cell exhaustion
Franco, F., Jaccard, A., Romero, P. J., Yu, Y.-R., & Ho, P. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00280-9 · Cited by 479
The multifaceted role of reactive oxygen species in tumorigenesis
Kirtonia, A., Sethi, G., & Garg, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03536-5 · Cited by 452
Mitochondrial control of immunity: beyond ATP
Mehta, M., Weinberg, S. E., & Chandel, N. S. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.66 · Cited by 409
Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399
Lactate-Lactylation Hands between Metabolic Reprogramming and Immunosuppression
Chen, L., Huang, L., Gu, Y. L., Cang, W., Sun, P., & Xiang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911943 · Cited by 380
“A combination of Metformin with anti-PD-1 improves T-cell function and tumor clearance in mice with melanoma [101].”
BackgroundWang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01820-7 · Cited by 315
“In contrast, inhibiting both oxygen consumption and subsequent tumor hypoxia with metformin has been correlated with a better efficacy of PD-1 blockade immunotherapy [96].”
BackgroundMethodInfluentialMolecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Fischer, G. M., Jalali, A., Kircher, D. A., Lee, W., McQuade, J. L., Haydu, L. E., Joon, A. Y., Reuben, A., de Macêdo, M. P., Carapeto, F. C. L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1489 · Cited by 324
“Metformin decreases intratumoral hypoxia that is highly detrimental to effector CD8+ T-cell function (53), and phenformin facilitates an increased response by preventing the immunosuppressive effects of myeloid-derived suppressor cells (55).”
BackgroundQuiescent cancer cells resist T cell attack by forming an immunosuppressive niche
Baldominos, P., Barbera-Mourelle, A., Barreiro, O., Huang, Y., Wight, A. E., Cho, J.-W., Zhao, X., Estivill, G., Adam, I., Sanchez, X., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.033 · Cited by 318
Menk, A. V., Scharping, N. E., Rivadeneira, D. B., Calderon, M. J., Watson, M. J., Dunstane, D., Watkins, S. C., & Delgoffe, G. M. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171068 · Cited by 322
“T cell metabolic output was measured by Seahorse technology as previously described (Scharping et al., 2017).”
MethodSelf-citationMetabolic interventions in the immune response to cancer
O’Sullivan, D., Sanin, D. E., Pearce, E. J., & Pearce, E. L. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0140-9 · Cited by 320
Targeting metabolism to regulate immune responses in autoimmunity and cancer
Patel, C. H., Leone, R. D., Horton, M. R., & Powell, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0032-5 · Cited by 311
Tsukamoto, H., Fujieda, K., Miyashita, A., Fukushima, S., Ikeda, T., Kubo, Y., Senju, S., Ihn, H., Nishimura, Y., & Oshiumi, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0118 · Cited by 305
“S4B and C), which might be due to the resistance to PD-1/PD-L1 blockade with their less-immunogenicity and hypoxic environment (15,34).”
BackgroundSun, J., Zhang, D., Wu, S., Xu, M., Zhou, X., Lu, X., & Ji, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00212-5 · Cited by 292
“Similarly, the combination of PD-1/PD-L1 blockade with tumor necrosis factor inhibitor [85, 86], metformin [87], anti-VEGF agents [88], or other immune checkpoint inhibitors (e.”
Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity
Vignali, P. D. A., DePeaux, K., Watson, M. J., Ye, C., Ford, B. R., Lontos, K., McGaa, N. K., Scharping, N. E., Menk, A. V., Robson, S. C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01379-9 · Cited by 269
Self-citationTargeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome
Salem, A., Asselin, M., Reymen, B. J. T., Jackson, A., Lambin, P., West, C., O’Connor, J. P. B., & Finn, C. F. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx160 · Cited by 267
Li, L., Wang, L., Li, J., Fan, Z., Li, Y., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 267
Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy
Ye, Y., Hu, Q., Chen, H., Liang, K., Yuan, Y., Xiang, Y., Ruan, H., Zhang, Z., Song, A., Zhang, H., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0045-8 · Cited by 258
Hypoxia as a driver of resistance to immunotherapy
Kopecka, J., Salaroglio, I. C., Pérez-Ruiz, E., Sarmento‐Ribeiro, A. B., Saponara, S., Rivas, J. D. L., & Riganti, C. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100787 · Cited by 264
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma
Najjar, Y. G., Menk, A. V., Sander, C., Rao, U. N. M., Karunamurthy, A. D., Bhatia, R., Zhai, S., Kirkwood, J. M., & Delgoffe, G. M. (2019) · JCI Insight · doi:10.1172/jci.insight.124989 · Cited by 240
“Further, we have previously shown in preclinical models that more oxidative tumors tend to be resistant to checkpoint blockade immunotherapy (16).”
BackgroundMethodInfluentialSelf-citationVaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 223
“This has been shown to decrease tumoral hypoxia, hereby augmenting intratumoral CD8+ T-cell activation and unlocking synergistic effects with checkpoint blockade in otherwise immunotherapyresistant tumors (114).”
BackgroundBruno, A., Mortara, L., Baci, D., Noonan, D. M., & Albini, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00771 · Cited by 223
“Phenformin and metformin were able to inhibit immune suppressive activities MDSCs and potentiated the anti-tumor activity of PD-1 blockade immunotherapy (236, 240, 241).”
BackgroundHu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z. F., He, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1022 · Cited by 213
Phase II clinical trial of metformin as a cancer stem cell–targeting agent in ovarian cancer
Brown, J. R., Chan, D., Shank, J., Griffith, K. A., Fan, H., Szulawski, R., Yang, K., Reynolds, R. K., Johnston, C., McLean, K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133247 · Cited by 203
Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing
Hua, Y., Zheng, Y., Yao, Y., Jia, R., Ge, S., & Zhuang, A. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04263-8 · Cited by 220
“Once tumors were larger than 10 mm2 before treatment in mice, metformin failed to exert synergistic effects with PD-1 blockade [183].”
BackgroundMetabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 210
Ma, S., Zhao, Y., Lee, W. C., Ong, L.-T., Lee, P. L., Jiang, Z., Oguz, G., Niu, Z., Liu, M., Goh, J. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31764-9 · Cited by 200
Role of mitochondrial alterations in human cancer progression and cancer immunity
Wang, S., Tseng, L., & Lee, H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00956-w · Cited by 225
Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells
Drijvers, J. M., Gillis, J. E., Muijlwijk, T., Nguyen, T. H., Gaudiano, E. F., Harris, I. S., LaFleur, M. W., Ringel, A. E., Yao, C.-H., Kurmi, K., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0384 · Cited by 191
Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy
Guerra, L., Bonetti, L., & Brenner, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107848 · Cited by 194
“Metformin can synergize with PD-1 ICB to improve intra-tumoral T cell function and cancer clearance in vivo (Scharping et al., 2017).”
BackgroundCurrent issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 188
“Metformin, which is used to treat type 2 diabetes, suppressed intratumoral oxygen consumption by tumor cells in vitro and in vivo, reduced the intratumoral hypoxic state, and improved intratumoral T cell function, when used in combination with PD-1 antibodies [83].”
BackgroundTumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
Hompland, T., Fjeldbo, C. S., & Lyng, H. (2021) · Cancers · doi:10.3390/cancers13030499 · Cited by 186
Nanoparticle‐Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy
Zhen, W., Weichselbaum, R. R., & Lin, W. (2022) · Advanced Materials · doi:10.1002/adma.202206370 · Cited by 188
Afzal, M. Z., Mercado, R. R., & Shirai, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0375-1 · Cited by 173
Wu, B., Shi, X., Jiang, M., & Liu, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01748-4 · Cited by 181
“kills cancer stem cells [256] while improving anti-PD-1 therapy efficacy [257].”
BackgroundGemta, L. F., Siska, P. J., Nelson, M. E., Gao, X., Liu, X., Locasale, J. W., Yagita∥, H., Slingluff, C. L., Hoehn, K. L., Rathmell, J. C., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aap9520 · Cited by 158
Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion
Kotsafti, A., Scarpa, M., Castagliuolo, I., & Scarpa, M. (2020) · Cancers · doi:10.3390/cancers12071748 · Cited by 161
“Another study showed a correlation between the ability of mouse tumor cell lines to consume oxygen and produce hypoxic environments with their sensitivity to PD-1 checkpoint blockade [125], thus suggesting that decreased levels of ROS and consequently a less hypoxic TME may intensify the effectiveness of PD-1 blockade…”
BackgroundThe role of AMPK in T cell metabolism and function
Ma, E. H., Poffenberger, M. C., Wong, A., & Jones, R. G. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.04.004 · Cited by 161
Kunisada, Y., Eikawa, S., Tomonobu, N., Domae, S., Uehara, T., Hori, S., Furusawa, Y., Hase, K., Sasaki, A., & Udono, H. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.10.009 · Cited by 152
“*P b 0.05; expression of the Met transporter OCT-1 (Slc22a1) is lower in T cells than in tumor cells (Scharping et al., 2016).”
BackgroundInfluentialMetabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
Wang, Y., Wang, Y., Ren, Y., Zhang, Q., Yi, P., & Cheng, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.010 · Cited by 148
Rivadeneira, D. B., DePeaux, K., Wang, Y., Kulkarni, A., Tabib, T., Menk, A. V., Sampath, P., Lafyatis, R., Ferris, R. L., Sarkar, S. N., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.07.003 · Cited by 142
Self-citationFundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy
Rivera, G. O. R., Knochelmann, H. M., Dwyer, C. J., Smith, A. S., Wyatt, M. M., Rivera-Reyes, A. M., Thaxton, J. E., & Paulos, C. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645242 · Cited by 154
“For example, metformin plus PD-1 therapy enhanced the antitumor capacity of endogenous T cells in mice, in part by reducing the hypoxic nature of the melanoma (173).”
BackgroundCompetitive glucose metabolism as a target to boost bladder cancer immunotherapy
Afonso, J., Santos, L. L., Longatto‐Filho, A., & Baltazar, F. (2020) · Nature Reviews Urology · doi:10.1038/s41585-019-0263-6 · Cited by 138
Tumor hypoxia represses γδ T cell-mediated antitumor immunity against brain tumors
Park, J. H., Kim, H.-J., Kim, C. W., Kim, H. C., Jung, Y., Lee, H., Lee, Y., Ju, Y. S., Oh, J. E., Park, S., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00860-7 · Cited by 137
Bigos, K. J. A., Quiles, C. G., Lunj, S., Smith, D. J., Krause, M., Troost, E. G. C., West, C., Hoskin, P., & Choudhury, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1331355 · Cited by 146
Augustin, R. C., Delgoffe, G. M., & Najjar, Y. G. (2020) · Cancers · doi:10.3390/cancers12123802 · Cited by 139
“Furthermore, the effects of hypoxia on CTL cytolytic capabilities have been mixed [35], although our work with antigen-specific T cells revealed lower IFN-γ levels and depressed cytolytic activity under acutely hypoxic conditions [36].”
MethodResultSelf-citationFu, Z., Mowday, A. M., Smaill, J. B., Hermans, I. F., & Patterson, A. V. (2021) · Cells · doi:10.3390/cells10051006 · Cited by 133
Functional polarization of tumor-associated macrophages dictated by metabolic reprogramming
Zeng, W., Li, F., Jin, S., Ho, P., Liu, P.-S., & Xie, X. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02832-9 · Cited by 139
“Preclinical evaluation of metabolic reprogramming of TAMs has shown promising effects with the drugs targeting arginine and tryptophan metabolism [105, 131, 149, 150], respiratory complex I inhibitor metformin [151, 152], inhibitors of extracellular adenosine and lactate production [153, 154], and FAO inhibitor [101,…”
BackgroundLequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01846-x · Cited by 129
Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy
Li, T. X., & Qiao, T. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.005 · Cited by 133
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?
Lord, S., & Harris, A. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02204-2 · Cited by 139
“Preclinical data have suggested that by remodelling the hypoxic tumour microenvironment metformin could potentiate the effect of anti PD-1 immunotherapy [44].”
BackgroundSpecialized immune responses in the peritoneal cavity and omentum
Liu, M., Silva-Sánchez, A., Randall, T. D., & Meza‐Perez, S. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mir0720-271rr · Cited by 135
Finisguerra, V., Dvořáková, T., Formenti, M., Meerbeeck, P. V., Mignion, L., Gallez, B., & den Eynde, B. J. V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005719 · Cited by 123
Uehara, T., Eikawa, S., Nishida, M., Kunisada, Y., Yoshida, A., Fujiwara, T., Kunisada, T., Ozaki, T., & Udono, H. (2018) · International Immunology · doi:10.1093/intimm/dxy079 · Cited by 120
Boreel, D. F., Span, P. N., Heskamp, S., Adema, G. J., & Bussink, J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3913 · Cited by 120
“Also, metformin administered every 2 days intraperitoneally was able to potentiate PD-1 blockade in MC38 mouse colon cancer and B16 melanoma models by improving CD8þ T-cell function through upregulation of immunologic checkpoints, thereby reducing tumor growth (13).”
BackgroundBroz, M. T., Ko, E. Y., Ishaya, K., Xiao, J.-F., Simone, M. C. D., Hoi, X. P., Piras, R., Gala, B., Tessaro, F. H. G., Karlstaedt, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46504-4 · Cited by 123
“Additionally, combining metformin, a common therapy for type 2 diabetes that reduces blood glucose levels, with anti-PD-1 treatment has shown promising outcomes in promoting T cell-dependent tumor regression and is currently being evaluated in clinical trials 67,68 .”
The role of ROS in tumor infiltrating immune cells and cancer immunotherapy
Shah, R., Ibis, B., Kashyap, M., & Boussiotis, V. A. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155747 · Cited by 119
Allison, K. E., Coomber, B. L., & Bridle, B. W. (2017) · Immunology · doi:10.1111/imm.12777 · Cited by 109
“Indeed, pre-clinical research has demonstrated the benefit of using metformin to counteract hypoxia in the tumour microenvironment, resulting in potentiation of PD-1 blockade(96).”
BackgroundCurrent Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy
Park, J. H., & Lee, H. K. (2022) · Cancers · doi:10.3390/cancers14051176 · Cited by 117
“Melanoma-infiltrating CD8+ T cells are also highly exhausted and malfunctional due to severe hypoxia [11].”
BackgroundLi, J., Zhang, G., Liu, C., Xiang, X., Le, M. T. N., Sethi, G., Wang, L., Goh, B.-C., & Ma, Z. (2021) · Theranostics · doi:10.7150/thno.64096 · Cited by 115
“interventions, including those associated with fatty acid oxidation and the respiratory complex I inhibitor, metformin [97, 98], have been successfully combined with immunotherapeutic agents to modulate anticancer effects [99].”
BackgroundLiu, Z., Liu, W., Wang, W., Ma, Y., Wang, Y., Drum, D. L., Cai, J., Blevins, H., Lee, E., Shah, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302878120 · Cited by 121
“…by a recent study showing that inhibiting tumor mitochondrial respiration with the mitochondrial complex 1 inhibitor metformin enhanced tumor response to anti - PD - 1 treatment through alleviating oxygen tension within the tumor microenvironment to improve T cell activation and function (53, 54).”
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 111
Nishida, M., Yamashita, N., Ogawa, T., Koseki, K., Warabi, E., Ohue, T., Komatsu, M., Matsushita, H., Kakimi, K., Kawakami, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002954 · Cited by 109
“8 The underlying mechanisms involved in these Met-dependent (as well as combination therapy) antitumor effects have remained elusive.”
Kidney tissue hypoxia dictates T cell–mediated injury in murine lupus nephritis
Chen, P.-M., Wilson, P. C., Shyer, J. A., Veselits, M., Steach, H. R., Cui, C., Moeckel, G. W., Clark, M. R., & Craft, J. E. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1620 · Cited by 103
Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs
Bailly, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117403 · Cited by 107
Ma, R., Yi, B., Riker, A. I., & Xi, Y. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00508-0 · Cited by 104
Takada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., Otsubo, K., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33557 · Cited by 100
“Many drugs, such as antibiotics, PPIs, probiotics, beta blockers, and metformin, affect the gastrointestinal microbiome, which may be an important factor in immune responses.(14-20,36-45) While most drugs have side effects and sometimes are deleterious to patients, pro-”
BackgroundMetformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
Verdura, S., Cuyàs, E., Martı́n-Castillo, B., & Menéndez, J. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1633235 · Cited by 99
“hypoxic TME results in a significantly improved intratumoral T-cell function and tumor clearance in pre-clinical models of highly aggressive tumors.(84) Such translational potential of metformin to convert immunotherapy-resistant patients into those showing clinical benefit has been supported by the discovery that”
BackgroundVerma, S., Budhu, S., Serganova, I. S., Dong, L., Mangarin, L. M. B., Khan, J. F., Bah, M. A., Assouvie, A., Marouf, Y., Schulze, I., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci177606 · Cited by 105
The effects of metformin on gut microbiota and the immune system as research frontiers
Pollak, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4352-x · Cited by 98
“Another study [38] also documented enhancement of PD-1 blockade as a cancer immunotherapy, but attributed this to a mechanism involving reduction of tumour hypoxia by the biguanide, which in turn was attributed to reduced oxygen consumption secondary to 1664 Diabetologia (2017) 60:1662–1667”
BackgroundAdipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
Wu, B., Sun, X., Gupta, H. B., Yuan, B., Li, J., Ge, F., Chiang, H.-C., Zhang, X., Zhang, C., Zhang, D., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1500107 · Cited by 98
“is worth noting that many obese male melanoma patients in this clinical study received anti-diabetic drugs,(58) which have been shown to enhance the antitumor activity of anti-PD-1 blockade in preclinical melanoma models.(59,60) A recent imaging-based study identified mouse brown adipose tissue (BAT), not WAT, as a si…”
BackgroundSkinner, H. D., Hu, C., Tsakiridis, T. K., Santana-Dávila, R., Lü, B., Erasmus, J. J., Doemer, A., Videtic, G. M. M., Coster, J. R., Yang, A. X., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2318 · Cited by 99
“Median (IQR) [range] 64 (58-72) [43-86] 63 (57-70) [47-82] 64 (58-71) [43-86]”
Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
Teijeira, Á., Labiano, S., Garasa, S., Etxeberría, I., Santamaría, E., Rouzaut, A., Enamorado, M., Azpilikueta, A., Inogés, S., Bolaños, E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0767 · Cited by 99
“Cumulative experimental evidence points tomitochondrial dysfunction of T cells in the tumor microenvironment (46), suggesting opportunity for interventions with metabolic drugs such as metformin (47).”
BackgroundAla, M., & Ala, M. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00167 · Cited by 97
Metformin: current clinical applications in nondiabetic patients with cancer
Chen, K., Li, Y., Guo, Z., Zeng, Y., Zhang, W., & Wang, H. (2020) · Aging · doi:10.18632/aging.102787 · Cited by 90
“com 4002 AGING checkpoint inhibitors have been demonstrated to enhance antitumor immune responses by the recovery of T cell function [109, 110].”
BackgroundSvatoň, M., Zemanová, M., Zemanová, P., Kultan, J., Fischer, O., Skřičková, J., Jakubíková, L., Černovská, M., Hrnčiarik, M., JIROUSEK, M., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14182 · Cited by 88
Drug repurposing to overcome resistance to various therapies for colorectal cancer
Fong, W., & To, K. K. W. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03134-0 · Cited by 81
Kao, T.-W., Bai, G.-H., Wang, T.-L., Shih, I.-M., Chuang, C.-M., Lo, C.-L., Tsai, M.-C., Chiu, L.-Y., Lin, C.-C., & Shen, Y.-A. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02724-y · Cited by 89
“gov/ compo und/ 4091 [155] Colon carcinoma (Mouse:MC38)”
BackgroundThe effect of extracellular vesicles on the regulation of mitochondria under hypoxia
Zhang, Y., Tan, J., Miao, Y., & Zhang, Q. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03640-9 · Cited by 92
Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy
Jayaprakash, P., Vignali, P., Delgoffe, G. M., & Curran, M. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-022830 · Cited by 87
Self-citationAfzal, M. Z., Dragnev, K. H., Sarwar, T., & Shirai, K. (2019) · Lung Cancer Management · doi:10.2217/lmt-2018-0016 · Cited by 90
Liu, X., Ye, N., Liu, S., Guan, J., Deng, Q., Zhang, Z., Xiao, C., Ding, Z., Zhang, B., Chen, X., et al. (2021) · Advanced Science · doi:10.1002/advs.202100233 · Cited by 83
Metadata
- Authors
- Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X., & Delgoffe, G. M.
- Affiliations
- University of Pittsburgh (US)
- UPMC Hillman Cancer Center (US)
- Corresponding author
- Delgoffe, Greg M.
- Venue
- Cancer Immunology Research
- Published
- 2017-01-01
- Volume
- 5
- Issue
- 1
- Pages
- 9-16
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC5340074
- OpenAlex
- W2560185130
- Cited by
- 520
- References
- 30
- Citations by year
- 2026: 34 · 2025: 53 · 2024: 49 · 2023: 72 · 2022: 85 · 2021: 79 · 2020: 69 · 2019: 38 · 2018: 30 · 2017: 11
- FWCI
- 14.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- UPCI (P30CA047904)
- Sidney Kimmel Foundation for Cancer Research (SKF-015-039)
- University of Pittsburgh Cancer Institute Skin Cancer (P50CA121973-08)
- University of Pittsburgh Cancer Institute Head and Neck Cancer SPORE (P50 CA097190)
- Cancer-AACR Innovative Research (SU2C-AACR-IRG-04-16)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- anti-PD-1 therapy, metformin, tumor hypoxia, tumor microenvironment, cancer immunotherapy resistance, combination therapy, oxidative metabolism, T cell function, B16 melanoma, MC38 colon carcinoma, antitumor immunity
- MeSH terms
- Tumor Hypoxia, Antineoplastic Agents, Immunological, Animals, Cytotoxicity, Immunologic, Drug Synergism, Energy Metabolism, Melanoma, Experimental, Metformin, Oxygen Consumption, T-Lymphocytes, Cytokines, Lymphocytes, Tumor-Infiltrating, Mice, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
